NYSE Euronext welcomes Movetis N.V. to its European market

Brussels, 4 December 2009 – Movetis, a Belgian pharmaceutical company, today listed on NYSE Euronext Brussels under the symbol 'MOVE'.

A total of 19,994,359 Movetis shares were admitted to trading on NYSE Euronext at an introductory price of EUR 12.25 each. The listing resulted from the offer of 13,055,583 existing shares and 6,938,776 new shares, before exercise of the over-allotment option. The amount raised by the initial public offering was EUR 85 million, excluding the over-allotment corresponding to EUR 12.75 million. At the opening, the first market price rose 2.9% to EUR 12.60, bringing the market capitalization of the company at EUR 252 million.

Attachments Available Languages
NYSE Euronext welcomes Movetis N.V. to its European market en

About Euronext
Euronext is the leading pan-European exchange in the Eurozone, covering Belgium, France, Ireland, The Netherlands, Portugal and the UK. With 1,300 listed issuers worth €3.9 trillion in market capitalisation as of end September 2018, Euronext is an unmatched blue chip franchise that has 24 issuers in the Morningstar® Eurozone 50 Index℠ and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs. 
For the latest news, find us on Twitter  (www.twitter.com/euronext) and LinkedIn (www.linkedin.com/company/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2018, Euronext N.V. - All rights reserved.